Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 28617K101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Vanguard Capital Management LLC 13G | 5.1% |
7/31/2026
Event 6/30/2026
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 11
|
10.0% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 6.8% | ||
| BVF I GP LLC | 6.8% | ||
| Biotechnology Value Fund II LP | 2.7% | ||
| BVF II GP LLC | 2.7% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 9.4% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
| BlackRock, Inc. 13G | 5.8% |
4/27/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/26/2026
Event 3/13/2026
|
|
|
RA Capital Management, L.P.
13G/A
Amendment 1
|
0% |
2/17/2026
Event 12/31/2025
|
|
| RA Capital Management, L.P. | 0% | ||
| Peter Kolchinsky | 0% | ||
| Rajeev Shah | 0% | ||
| RA Capital Healthcare Fund, L.P. | 0% | ||
|
Coastlands Capital LP
13G/A
Amendment 1
|
4.99% |
2/13/2026
Event 12/31/2025
|
|
| Coastlands Capital LP | 4.99% | ||
| Coastlands Capital Partners LP | 4.99% | ||
| Coastlands Capital GP LLC | 4.99% | ||
| Coastlands Capital LLC | 4.99% | ||
| Matthew D. Perry | 4.99% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.6% |
1/21/2026
Event 12/31/2025
|
|
|
Coastlands Capital LP
13G
|
6.0% |
11/24/2025
Event 11/19/2025
|
|
| Coastlands Capital LP | 5.3% | ||
| Coastlands Capital Partners LP | 5.3% | ||
| Coastlands Capital GP LLC | 5.3% | ||
| Coastlands Capital LLC | 5.3% | ||
| Matthew D. Perry | 6.0% | ||
| Vanguard Group Inc 13G | 5.5% |
7/29/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G | 5.4% |
7/17/2025
Event 6/30/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
2.0% |
2/14/2025
Event 12/31/2024
|
|
| Frazier Life Sciences Public Fund, L.P. | 1.5% | ||
| FHMLSP, L.P. | 1.5% | ||
| FHMLSP, L.L.C. | 1.5% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.4% | ||
| FHMLSP Overage, L.P. | 0.4% | ||
| FHMLSP Overage, L.L.C. | 0.4% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 2.0% | ||
| Patrick J. Heron | 2.0% | ||
| Albert Cha | 1.9% | ||
| James Brush | 1.9% | ||
| Daniel Estes | 0% | ||
|
Armistice Capital, LLC
13G/A
Amendment 2
|
4.99% |
2/14/2025
Event 12/31/2024
|
|
| Armistice Capital, LLC | 4.99% | ||
| Steven Boyd | 4.99% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 7 | 21.6 k | $54.7 k |
| 2026 Q2 | 170 | 46.9 M | $186 M |
| 2026 Q1 | 124 | 42.6 M | $131 M |
| 2025 Q4 | 99 | 44.2 M | $66.7 M |
| 2025 Q3 | 89 | 36.5 M | $94.5 M |
| 2025 Q2 | 90 | 40.9 M | $111 M |
| 2025 Q1 | 87 | 38.4 M | $130 M |
| 2024 Q4 | 79 | 38.5 M | $159 M |
| 2024 Q3 | 35 | 18.5 M | $46.0 M |
| 2024 Q2 | 36 | 18.9 M | $49.8 M |
| 2024 Q1 | 35 | 9.60 M | $19.8 M |
| 2023 Q4 | 33 | 9.16 M | $16.5 M |
| 2023 Q3 | 29 | 8.92 M | $12.2 M |
| 2023 Q2 | 35 | 9.28 M | $12.7 M |
| 2023 Q1 | 33 | 6.24 M | $14.7 M |
| 2022 Q4 | 30 | 6.30 M | $14.5 M |
| 2022 Q3 | 33 | 6.27 M | $17.3 M |
| 2022 Q2 | 33 | 6.54 M | $15.9 M |
| 2022 Q1 | 34 | 7.01 M | $27.6 M |
| 2021 Q4 | 40 | 7.88 M | $34.7 M |
| 2021 Q3 | 37 | 8.43 M | $52.1 M |
| 2021 Q2 | 35 | 9.42 M | $74.5 M |
| 2021 Q1 | 35 | 8.32 M | $89.0 M |
| 2020 Q4 | 2 | 36.1 k | $556 k |